Department of Chemistry and Biochemistry Seminar
- Friday, January 13, 2017 from 3:10pm to 4:00pm
- Chemistry and Biochemistry Building - view map
Dr. James Crawford, a Senior Scientist and Project Team Leader in Small Molecule Drug Discovery at Genentech will present "Discovery of GDC-0853: A Highly Potent, Selective,and Non-Covalent Btk Inhibitor."
Bio: Dr. Crawford was born and raised in Glasgow, Scotland, and attended the University of Strathclyde where he obtained his MSci, followed by his Ph.D., working with Professors Kerr (University of Strathclyde) and Henderson (University of Notre Dame, IN). In 2005 he joined Professor K.C. Nicolaou’s laboratory at The Scripps Research Institute as a Fulbright scholar.
James started his industrial career in late 2006 at AstraZeneca’s Alderley Park site as an Associate Team Leader in Medicinal Chemistry, where he was part of the team that identified a development compound for the inhibition of the cysteine protease Cathepsin K as a treatment for osteoarthritis. A move to AZ’s Charnwood site followed, where he was the lead chemist on a number of Hit Identification projects (including viral, TLR, GPCR and protease targets).
After 4 years with AZ, and having clearly missed the Californian weather, James joined Genentech in San Francisco. During his time at Genentech, James has worked across three disease areas – Immunology, Oncology and Antibacterials. One of his key roles has been as the chemistry leader of the BTK discovery team at Genentech, leading a team co-located in San Francisco and Shanghai.
- Department of Chemistry and Biochemistry